Figures & data
Figure 1. Genomic (slow) and non-genomic (rapid) mechanisms of action of PR complexes (PRA; PRB). Non-genomic signaling requires a membrane progesterone receptor (mPR) that stimulates a cascade which induces CBP phosphorylation and stimulation of co-activators involved in the genomic mechanism.
![Figure 1. Genomic (slow) and non-genomic (rapid) mechanisms of action of PR complexes (PRA; PRB). Non-genomic signaling requires a membrane progesterone receptor (mPR) that stimulates a cascade which induces CBP phosphorylation and stimulation of co-activators involved in the genomic mechanism.](/cms/asset/945e407d-31cc-4b9e-9690-53817d586bdf/ienz_a_895719_f0001_c.jpg)
Figure 2. Progestins structurally related to progesterone. 1 – Progesterone, 2 – testosterone, 3 – 17-α-hydroxyprogesterone, 4 – 17α-acetoxyprogesterone, 5 – medroxyprogesterone acetate, 6 – chlormadinone acetate and 7 – cyproterone acetate.
![Figure 2. Progestins structurally related to progesterone. 1 – Progesterone, 2 – testosterone, 3 – 17-α-hydroxyprogesterone, 4 – 17α-acetoxyprogesterone, 5 – medroxyprogesterone acetate, 6 – chlormadinone acetate and 7 – cyproterone acetate.](/cms/asset/0836b2fd-373d-44e8-bf3c-5f0d12c1f103/ienz_a_895719_f0002_b.jpg)
Figure 6. 17-β-Methyl, 16-β-phenyl-D-homoandrost-4,6-diene derivatives having a phenylacetic acid ester at C-17β position and dehydroepiandrosterone derivatives as an antagonists and partial antagonists. 5α-Reductase enzyme IC50 (5α-R IC50) is the concentration of the synthetic steroid to produce 50% inhibition of 5α-R activity.
![Figure 6. 17-β-Methyl, 16-β-phenyl-D-homoandrost-4,6-diene derivatives having a phenylacetic acid ester at C-17β position and dehydroepiandrosterone derivatives as an antagonists and partial antagonists. 5α-Reductase enzyme IC50 (5α-R IC50) is the concentration of the synthetic steroid to produce 50% inhibition of 5α-R activity.](/cms/asset/dc18eb2a-0529-4f99-a71c-d683ef77fa33/ienz_a_895719_f0006_b.jpg)
Figure 7. Halogen-substituted phenylacetic acid derivatives antagonists of PR. Androgen receptor (AR), glucocorticoid receptor (GR), mineralocorticoid receptor (MR). RBA, Relative binding affinity; PR, Progesterone receptor; AR, Androgen receptor; GR, glucocoticoid receptor; MR, mineralocorticoid receptor; NA, Non-active.
![Figure 7. Halogen-substituted phenylacetic acid derivatives antagonists of PR. Androgen receptor (AR), glucocorticoid receptor (GR), mineralocorticoid receptor (MR). RBA, Relative binding affinity; PR, Progesterone receptor; AR, Androgen receptor; GR, glucocoticoid receptor; MR, mineralocorticoid receptor; NA, Non-active.](/cms/asset/4dd777bb-4a9d-423b-91a6-b505ad94b690/ienz_a_895719_f0007_b.jpg)